We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A bipartisan group of influential senators is pressuring PhRMA President Billy Tauzin to continue offering patient prescription programs (PAPs) to Medicare recipients.
A bi-partisan coalition of senators, including Chuck Grassley (R-Iowa), Max Baucus (D-Mont.) Orrin Hatch (R-Utah) and Jay Rockefeller (D-W.Va.) petitioned HHS Inspector General Daniel Levinson April 17 to address drug companies participation in patient assistance programs (PAPs).
The Medicare prescription drug plan is nearing its goal of 28–30 million enrollees in the first year, but still faces criticism from congressional opponents who argue that most of the plans restrict access to drugs.
House Democrats’ effort to clear the way for HHS to directly negotiate Medicare drug prices suffered a major defeat last week after their budget amendment lost on a party-line vote in the House Budget Committee.
The Medicare prescription drug plan is nearing its goal of 28–30 million enrollees in the first year, but still faces criticism from congressional opponents.
The House Rules Committee seems poised to block House Democrats’ efforts to clear the way for HHS to directly negotiate Medicare drug prices, committee staffers say.
California has put on hold its plans to join a multistate lawsuit challenging a key provision in the new Medicare prescription drug benefit, according to state Attorney General Bill Lockyer.
A new report from a pharmaceutical benefit manager group says Medicare enrollees are paying less for drugs through the new Medicare Rx drug benefit, but several government reports released on the same day assert drug prices are actually higher under the new program.